WASHINGTON — Supporters of a Senate-passed “right-to-try” bill that aims to help terminally ill patients gain access to experimental treatments are pushing for the House to act quickly on the measure — but key House leaders showed little interest in that push.

Sen. Ron Johnson (R-Wis.), who threatened to hold up a bipartisan and timely package of Food and Drug Administration policies in August in order to push his right-to-try legislation through the Senate, called on the House this week to pass his bill without changing a word. Any modifications in the House would force the Senate to reconsider the bill anew.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy